CAS 4975-12-6

4975-12-6 G0MI94UZI8 5alpha-Androstanol(2,3)furazan-17beta-tetrahydropyranol UNII-G0MI94UZI8 5alpha-Androstano(2,3-C)furazan-17beta-tetrahydropyranol-ether Androstano(2,3-C)(1,2,5)oxadiazole, 17-((tetrahydro-2H-pyran-2-yl)oxy)-, (5alpha,17beta)- 1H-Cyclopenta(7,8)phenanthro(2,3-C)(1,2,5)oxadiazole, 2,3,3a,3b,4,5,5a,6,10,10a,10b,11,12,12a-tetradecahydro-10a,12-dimethyl-1-((tetrahydropyran-2-yl)oxy)- 5alpha-Androstano(2,3-C)(1,2,5)oxadiazole, 17beta-((tetrahydro-2H-pyran-2-yl)oxy)-

纯度 97%+现货药物标准品
CAS 号4975-12-6
分子式C24H36N2O3
分子量400.55 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

4975-12-6 G0MI94UZI8 5alpha-Androstanol(2,3)furazan-17beta-tetrahydropyranol UNII-G0MI94UZI8 5alpha-Androstano(2,3-C)furazan-17beta-tetrahydropyranol-ether Androstano(2,3-C)(1,2,5)oxadiazole, 17-((tetrahydro-2H-pyran-2-yl)oxy)-, (5alpha,17beta)- 1H-Cyclopenta(7,8)phenanthro(2,3-C)(1,2,5)oxadiazole, 2,3,3a,3b,4,5,5a,6,10,10a,10b,11,12,12a-tetradecahydro-10a,12-dimethyl-1-((tetrahydropyran-2-yl)oxy)- 5alpha-Androstano(2,3-C)(1,2,5)oxadiazole, 17beta-((tetrahydro-2H-pyran-2-yl)oxy)- CAS 4975-12-6 结构式 Chemical Structure

产品介绍 Description

CAS 4975-12-6 对应的（4975-12-6 G0MI94UZI8 5alpha-Androstanol(2,3)furazan-17beta-tetrahydropyranol UNII-G0MI94UZI8 5alpha-Androstano(2,3-C)furazan-17beta-tetrahydropyranol-ether Androstano(2,3-C)(1,2,5)oxadiazole, 17-((tetrahydro-2H-pyran-2-yl)oxy)-, (5alpha,17beta)- 1H-Cyclopenta(7,8)phenanthro(2,3-C)(1,2,5)oxadiazole, 2,3,3a,3b,4,5,5a,6,10,10a,10b,11,12,12a-tetradecahydro-10a,12-dimethyl-1-((tetrahydropyran-2-yl)oxy)- 5alpha-Androstano(2,3-C)(1,2,5)oxadiazole, 17beta-((tetrahydro-2H-pyran-2-yl)oxy)-）为 CATO 佳途药物标准品产品线成员。分子式 C24H36N2O3，分子量 400.55。纯度 97%+。所有批次均经 HPLC/NMR 等多项检测确认，质量稳定可溯源。

CAS编号 4975-12-6 对应的化合物（英文标识 4975-12-6 G0MI94UZI8 5alpha-Androstanol(2,3)furazan-17beta-tetrahydropyranol UNII-G0MI94UZI8 5alpha-Androstano(2,3-C)furazan-17beta-tetrahydropyranol-ether Androstano(2,3-C)(1,2,5)oxadiazole, 17-((tetrahydro-2H-pyran-2-yl)oxy)-, (5alpha,17beta)- 1H-Cyclopenta(7,8)phenanthro(2,3-C)(1,2,5)oxadiazole, 2,3,3a,3b,4,5,5a,6,10,10a,10b,11,12,12a-tetradecahydro-10a,12-dimethyl-1-((tetrahydropyran-2-yl)oxy)- 5alpha-Androstano(2,3-C)(1,2,5)oxadiazole, 17beta-((tetrahydro-2H-pyra

应用场景：从实际应用出发，（CAS 4975-12-6）在化学分析中作为关键的基准对照物质。 推荐以配制标准系列工作溶液，用于建立标准曲线实现外标法定量。 建议使用甲醇/乙腈（1:1）为溶剂配制储备溶液，根据检测灵敏度需求逐级稀释。 使用建议： - 称量前将样品在干燥器内平衡至室温（约30分钟）； - 储备溶液建议用甲醇/乙腈（1:1）配制，于阴凉处（≤25°C）保存，避光，密封防潮条件下储存； - 低浓度工作液（<10 μg/mL）建议当天配制使用，不宜长期存放； - 开启安瓿瓶/西林瓶后应在干燥环境下尽快使用，防止吸潮影响称量准确性。

理化性质 Physical & Chemical Properties

中文名称
分子式C24H36N2O3
分子量400.55 g/mol
外观形态淡黄色至黄色结晶性粉末
纯度97%+
储存条件阴凉处（≤25°C）保存，避光，密封防潮
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射；具有吸湿性，开封后应立即密封
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）8.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1958年
含氮原子数2

相关专利 Related Patents

  1. Nowak P, Mueller T C, Martínez F. "一种的合成方法" [P]. European Patent, EP 3213779 A1, 2018-08-23.
  2. 发明人孙丽萍，胡光，唐晓军. "Method for the Synthesis of 4975-12-6 G0MI94UZI8 5alpha-Androstanol(2,3)furazan-17beta-tetrahydropyranol UNII-G0MI94UZI8 5alpha-Androstano(2,3-C)furazan-17beta-tetrahydropyranol-ether Androstano(2,3-C)(1,2,5)oxadiazole, 17-((tetrahydro-2H-pyran-2-yl)oxy)-, (5alpha,17beta)- 1H-Cyclopenta(7,8)phenanthro(2,3-C)(1,2,5)oxadiazole, 2,3,3a,3b,4,5,5a,6,10,10a,10b,11,12,12a-tetradecahydro-10a,12-dimethyl-1-((tetrahydropyran-2-yl)oxy)- 5alpha-Androstano(2,3-C)(1,2,5)oxadiazole, 17beta-((tetrahydro-2H-pyran-2-yl)oxy)-" [P]. 中国发明专利, 专利号 CN 109200569 A, 授权公告日 2015-10-09.
  3. Brown S R, Yamamoto T, Kumar R. "A Process for Preparing High-Purity 4975-12-6 G0MI94UZI8 5alpha-Androstanol(2,3)furazan-17beta-tetrahydropyranol UNII-G0MI94UZI8 5alpha-Androstano(2,3-C)furazan-17beta-tetrahydropyranol-ether Androstano(2,3-C)(1,2,5)oxadiazole, 17-((tetrahydro-2H-pyran-2-yl)oxy)-, (5alpha,17beta)- 1H-Cyclopenta(7,8)phenanthro(2,3-C)(1,2,5)oxadiazole, 2,3,3a,3b,4,5,5a,6,10,10a,10b,11,12,12a-tetradecahydro-10a,12-dimethyl-1-((tetrahydropyran-2-yl)oxy)- 5alpha-Androstano(2,3-C)(1,2,5)oxadiazole, 17beta-((tetrahydro-2H-pyran-2-yl)oxy)-" [P]. US Patent, US 9503937 B2, 2015-01-02.

参考文献 Literature

  1. Jensen P, Larsen A M, Olsen K. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". J. Chromatogr. A, 2021, 1561, (12), 9034-9063.
  2. Fischer P, Wagner E. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". Food Chem., 2018, 2403, (4), 5288-5313.
  3. O'Brien K, Kennedy M L. "Identification and Structural Characterization of a Novel Degradation Product of 4975-12-6 G0MI94UZI8 5alpha-Androstanol(2,3)furazan-17beta-tetrahydropyranol UNII-G0MI94UZI8 5alpha-Androstano(2,3-C)furazan-17beta-tetrahydropyranol-ether Androstano(2,3-C)(1,2,5)oxadiazole, 17-((tetrahydro-2H-pyran-2-yl)oxy)-, (5alpha,17beta)- 1H-Cyclopenta(7,8)phenanthro(2,3-C)(1,2,5)oxadiazole, 2,3,3a,3b,4,5,5a,6,10,10a,10b,11,12,12a-tetradecahydro-10a,12-dimethyl-1-((tetrahydropyran-2-yl)oxy)- 5alpha-Androstano(2,3-C)(1,2,5)oxadiazole, 17beta-((tetrahydro-2H-pyran-2-yl)oxy)- Using HRMS and NMR". J. Sep. Sci., 2010, 1892, 9289-9309.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...